PET Imaging Study Links Long COVID Symptoms to Reduced Striatal Dopamine Terminals

The trial used a validated PET ligand to quantify dopamine nerve terminal integrity in the ventral striatum, dorsal putamen, and caudate of participants with persistent post-COVID symptoms. Lower binding was observed in all three regions relative to healthy volunteers, extending the group’s prior observation of elevated neuroinflammation in the same dopamine-rich territories. Symptom mapping showed ventral-striatal reductions tracked with apathy scores, putaminal loss with motor slowing, and caudate changes with episodic-memory impairment.

These regional patterns mirror the topography of dopamine loss seen in Parkinson disease and other inflammatory basal-ganglia disorders, suggesting that SARS-CoV-2-triggered microglial activation may produce lasting terminal injury rather than reversible functional suppression. The absence of quantitative effect sizes or participant numbers in the report limits immediate clinical translation, yet the anatomical specificity strengthens the mechanistic hypothesis over purely psychological explanations.

Repurposing dopamine precursors or reuptake inhibitors, already approved for other indications, is now being prepared for a targeted proof-of-concept trial. If the upcoming study demonstrates symptom improvement tied to restored dopaminergic tone, it would shift long-COVID management from supportive care toward mechanism-based pharmacotherapy.

Key unanswered questions include whether the observed marker loss reflects irreversible neuronal death or a partially reversible inflammatory state, and whether similar PET changes appear in non-COVID post-viral fatigue syndromes.